Transcriptomics

Dataset Information

5

HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancer


ABSTRACT: We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that patients with HTICS+ HER2+:ERα− tumors are more likely to achieve a pathologic complete response to trastuzumab-based neoadjuvant chemotherapy compared with HER2+:ER+ tumors. Neoadjuvant study of 50 HER2-positive breast cancer cases treated with trastuzumab-based chemotherapy pre-operatively. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to Affymetrix microarrays according to manufacturer protocol. Pathologic response was assessed at the end of neoadjuvant treatment.

ORGANISM(S): Homo sapiens  

SUBMITTER: Francisco J Esteva   William F Symmans  Lajos Pusztai  Francisco J. Esteva 

PROVIDER: E-GEOD-37946 | ArrayExpress | 2012-05-11

SECONDARY ACCESSION(S): GSE37946PRJNA165715

REPOSITORIES: GEO, ArrayExpress

Similar Datasets

2012-05-12 | GSE37946 | GEO
2016-03-31 | E-GEOD-62327 | ArrayExpress
| GSE66305 | GEO
| GSE66398 | GEO
2015-10-19 | E-GEOD-55348 | ArrayExpress
2011-05-11 | E-GEOD-25055 | ArrayExpress
2011-05-11 | E-GEOD-25065 | ArrayExpress
2015-06-25 | E-GEOD-70233 | ArrayExpress
| GSE50948 | GEO
2013-09-03 | E-GEOD-41118 | ArrayExpress